share_log

中國生物製藥：2023 環境、社會及管治報告

SINO BIOPHARM: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

Hong Kong Stock Exchange ·  Apr 29 04:28
Summary by Moomoo AI
中國生物製藥有限公司於2023年發佈了其環境、社會及管治（ESG）報告，全面展示了公司在ESG領域的管理實踐和成效。報告遵循重要性、量化、平衡和一致性原則，並依據香港聯合交易所有限公司《主板上市規則》附錄C2《環境、社會及管治報告指引》編製。報告範圍與《中國生物製藥有限公司2023年度報告》一致，信息來源包括集團內部管理文件及相關記錄。報告週期為2023年1月1日至12月31日，部分內容追溯歷史信息。報告中，公司詳細披露了其在氣候變化應對、資源使用、廢棄物管理、供應鏈管理、產品質量、員工培訓與發展、多元化與平等機會等方面的政策、實踐及成效。此外，報告經英國標準協會獨立鑒證，確認報告內容真實、完整。中國生物製藥通過此報告展現了其對提升企業可持續發展能力的承諾與努力。
中國生物製藥有限公司於2023年發佈了其環境、社會及管治（ESG）報告，全面展示了公司在ESG領域的管理實踐和成效。報告遵循重要性、量化、平衡和一致性原則，並依據香港聯合交易所有限公司《主板上市規則》附錄C2《環境、社會及管治報告指引》編製。報告範圍與《中國生物製藥有限公司2023年度報告》一致，信息來源包括集團內部管理文件及相關記錄。報告週期為2023年1月1日至12月31日，部分內容追溯歷史信息。報告中，公司詳細披露了其在氣候變化應對、資源使用、廢棄物管理、供應鏈管理、產品質量、員工培訓與發展、多元化與平等機會等方面的政策、實踐及成效。此外，報告經英國標準協會獨立鑒證，確認報告內容真實、完整。中國生物製藥通過此報告展現了其對提升企業可持續發展能力的承諾與努力。
China Biopharmaceuticals Limited published its Environmental, Social and Governance (ESG) Report in 2023, which comprehensively showcases the company's management practices and performance in the field of ESG. The report follows the principles of materiality, quantification, balance and consistency and is based on the Environmental, Social and Governance Reporting Guidelines, Appendix C2 of the Main Board Listing Rules of Hong Kong Stock Exchange Limited. The scope of the report is consistent with the Annual Report of China Biopharmaceuticals Limited 2023. Sources of information include the Group's internal management documents and related records. The reporting period is January 1 to December 31, 2023, with some historical information backdating. In the report, the company discloses in detail its policies, practices and performance in addressing climate change, resource...Show More
China Biopharmaceuticals Limited published its Environmental, Social and Governance (ESG) Report in 2023, which comprehensively showcases the company's management practices and performance in the field of ESG. The report follows the principles of materiality, quantification, balance and consistency and is based on the Environmental, Social and Governance Reporting Guidelines, Appendix C2 of the Main Board Listing Rules of Hong Kong Stock Exchange Limited. The scope of the report is consistent with the Annual Report of China Biopharmaceuticals Limited 2023. Sources of information include the Group's internal management documents and related records. The reporting period is January 1 to December 31, 2023, with some historical information backdating. In the report, the company discloses in detail its policies, practices and performance in addressing climate change, resource use, waste management, supply chain management, product quality, employee training and development, diversity and equal opportunities. In addition, the report is independently verified by the British Standards Association to confirm that the content of the report is authentic and complete. Through this report, China Biopharmaceuticals demonstrates its commitment and efforts to enhance the sustainability capabilities of enterprises.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more